<- Go Home
Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Market Cap
CHF 35.4B
Volume
762.3K
Cash and Equivalents
CHF 1.3B
EBITDA
CHF 1.6B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 5.6B
Profit Margin
47.94%
52 Week High
CHF 93.04
52 Week Low
CHF 53.76
Dividend
1.20%
Price / Book Value
3.95
Price / Earnings
55.71
Price / Tangible Book Value
-45.44
Enterprise Value
CHF 39.3B
Enterprise Value / EBITDA
23.74
Operating Income
CHF 1.1B
Return on Equity
7.25%
Return on Assets
3.07
Cash and Short Term Investments
CHF 2.3B
Debt
CHF 6.2B
Equity
CHF 9.0B
Revenue
CHF 11.7B
Unlevered FCF
CHF 1.5B
Sector
Pharmaceuticals
Category
N/A